Implementing the 2022 ACC/AHA/HFSA Guideline for the Management of Heart Failure: SGLT2 Inhibitors, Treatment Sequencing, and Value Statements

home / publications / supplement / implement-2022-acc-heart-failure-guideline-sglt2-treatment-sequence-value-statements

Key Takeaways from the 2022 ACC/AHA/HFSA Guideline for the Management of Heart Failure

Insight from the Writing Committee Chair of the 2022 ACC/AHA/HFSA Guideline for the Management of Heart Failure

A Q&A With Paul Heidenreich, MD

Rapid Sequencing of the Four Pillars of Heart Failure Treatment

A Q&A With Milton Packer, MD

Kaiser Permanente’s Clinical Pathway for the Early Use of SGLT2 Inhibitors

A Q&A With Gary Besinque, PharmD

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2024 MJH Life Sciences^® and AJMC®.
All rights reserved.

Editorial Boards

Do Not Sell My Information

Terms & Conditions